629. High Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in African American Adults with HIV Including Those with Preexisting Resistance, Viral Blips, and Suboptimal Adherence

BACKGROUND: BRAAVE 2020 demonstrated the efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) among African American adults with suppressed HIV through Week (W) 48 (Figure 1). We present resistance, viral blips, adherence, and virologic outcomes through W72. Figure 1. B...

Descripción completa

Detalles Bibliográficos
Autores principales: Andreatta, Kristen, D'Antoni, Michelle L, Chang, Silvia, Parvangada, Aiyappa, Martin, Ross, Blair, Christiana, Collins, Sean E, White, Kirsten L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644937/
http://dx.doi.org/10.1093/ofid/ofab466.827

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644937/
http://dx.doi.org/10.1093/ofid/ofab466.827

Ejemplares similares